Skip to main content
. 2022 Aug 25;13:967633. doi: 10.3389/fphar.2022.967633

TABLE 2.

Phase II clinical trials of PARPis plus other drugs in OC/TNBC with published results.

Clinicaltrials. Gov identifier/Study name Condition or disease Treatment arm Patients Key outcome measures
NCT02734004/MEDIOLA BRCA1/2-mutated metastatic breast cancer durvalumab + olaparib 30 DCR of 12 weeks: 80% (N = 24), 90% CI, 64.3–90.9
NCT03579316 Recurrent PARPi-resistant ovarian cancer adavosertib 35 ORR: 23% (90% CI)
CBR: 63% (90% CI)
PFS: 5.5 months (90%CI)
Adavosertib + olaparib 35 ORR: 29% (90% CI)
CBR: 89% (90% CI)
PFS: 6.8 months (90%CI)
NCT02657889 Triple-negative Breast Cancer Pembrolizumab + niraparib 55 ORR:21%, (90% CI, 12%–33%)
DCR:49%, (90% CI, 36%–62%)
CR:5 patients (9%)
PR: 5 patients (9%)
SD: 13 patients (24%)
Ovarian cancer 60 ORR: 18% (90% CI, 11%–29%)
DCR: 65% (90% CI, 54%–75%)
CR:3 patients (5%)
PR: 8 patients (13%)
SD: 28 patients (47%)
NCT02354131/AVANOVA2 Platinum-sensitive recurrent ovarian cancer Niraparib plus bevacizumab 48 PFS:11·9 months (95% CI 8·5–16·7)
Niraparib 49 PFS: 5.5 months (95% CI 8·5–16·7)